Triple therapy before lung cancer surgery shows promise in major trial
NCT ID NCT06437977
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests whether adding targeted radiation (SBRT) to immunotherapy (toripalimab) and chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. About 478 participants will be randomly assigned to receive either the triple combination or just immunotherapy plus chemo. The main goals are to see if the triple therapy delays cancer return and increases the chance of no cancer being found in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II-III NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.